title: Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome.
abstract: The growth hormone (GH)-activated transcription factor signal transducer and activator of transcription 5b (STAT5b) is a key regulator of sexually dimorphic gene expression in the liver. Suppression of hepatic STAT5b signaling is associated with lipid metabolic dysfunction leading to steatosis and liver cancer. In the companion publication, a STAT5b biomarker gene set was identified and used in a rank-based test to predict both increases and decreases in liver STAT5b activation status/function with high (≥ 97%) accuracy. Here, this computational approach was used to identify chemicals and hormones that activate (masculinize) or suppress (feminize) STAT5b function in a large, annotated mouse liver and primary hepatocyte gene expression compendium. Exposure to dihydrotestosterone and thyroid hormone caused liver masculinization, whereas glucocorticoids, fibroblast growth factor 15, and angiotensin II caused liver feminization. In mouse models of diabetes and obesity, liver feminization was consistently observed and was at least partially reversed by leptin or resveratrol exposure. Chemical-induced feminization of male mouse liver gene expression profiles was a relatively frequent phenomenon: of 156 gene expression biosets from chemically-treated male mice, 29% showed feminization of liver STAT5b function, while <1% showed masculinization. Most (93%) of the biosets that exhibited feminization of male liver were also associated with activation of one or more xenobiotic-responsive receptors, most commonly constitutive activated receptor (CAR) or peroxisome proliferator-activated receptor alpha (PPARα). Feminization was consistently associated with increased expression of peroxisome proliferator-activated receptor gamma (Pparg) but not other lipogenic transcription factors linked to steatosis. GH-activated STAT5b signaling in mouse liver is thus commonly altered by diverse chemicals, and provides a linkage between chemical exposure and dysregulated gene expression associated with adverse effects on the liver.
authors.affiliation: Integrated Systems Toxicology Division, National Health and Environmental Effects Research Laboratory/ Office of Research and Development, United States Environmental Protection Agency, Research Triangle Park, North Carolina, United States of America.
authors.forename: Keiyu
authors.initials: K
authors.lastname: Oshida
authors.affiliation: Division of Cell and Molecular Biology, Department of Biology and Bioinformatics Program, Boston University, Boston, MA 02215, United States of America.
authors.forename: David J
authors.initials: DJ
authors.lastname: Waxman
authors.affiliation: Integrated Systems Toxicology Division, National Health and Environmental Effects Research Laboratory/ Office of Research and Development, United States Environmental Protection Agency, Research Triangle Park, North Carolina, United States of America.
authors.forename: J Christopher
authors.initials: JC
authors.lastname: Corton
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D019295:Computational Biology; D013196:Dihydrotestosterone / Q000494:pharmacology; D005260:Female; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D050799:STAT5 Transcription Factor / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D013963:Thyroid Hormones / Q000494:pharmacology; D059467:Transcriptome / Q000235:genetics*
chemical_list: D005938:Glucocorticoids; D050799:STAT5 Transcription Factor; D013963:Thyroid Hormones; D013196:Dihydrotestosterone; D000804:Angiotensin II; D005346:Fibroblast Growth Factors